Phosphorylation-dependent Stabilization of MZF1 Upregulates N-cadherin Expression During Protein Kinase CK2-mediated Epithelial-mesenchymal Transition
Overview
Affiliations
Epithelial-mesenchymal transition (EMT) is a critical process in invasion and metastasis of cancer cells. E-cadherin to N-cadherin switching is considered a molecular hallmark of EMT. Recently, we reported that increased CK2 activity fully induces E-cadherin to N-cadherin switching, but the molecular mechanisms of N-cadherin upregulation are unknown. In this study, we examined how N-cadherin is upregulated by CK2. N-cadherin promoter analysis and ChIP analysis identified and confirmed myeloid zinc finger 1 (MZF1) as an N-cadherin transcription factor. Molecular analysis showed that MZF1 directly interacts with CK2 and is phosphorylated at serine 27. Phosphorylation stabilizes MZF1 and induces transcription of N-cadherin. MZF1 knockdown (MKD) in N-cadherin-expressing cancer cells downregulates N-cadherin expression and reverts the morphology from spindle and fibroblast-like to a rounded, epithelial shape. In addition, we showed that that MKD reduced the motility and invasiveness of N-cadherin-expressing cancer cells. Collectively, these data indicate that N-cadherin upregulation in CK2-mediated E-cadherin to N-cadherin switching is dependent on phosphorylation-mediated MZF1 stabilization. CK2 could be a good therapeutic target for the prevention of metastasis.
Wang H, Li Y, Wu N, Lv C, Wang Y BMC Nephrol. 2024; 25(1):297.
PMID: 39251943 PMC: 11385120. DOI: 10.1186/s12882-024-03733-5.
YAP1 controls the N-cadherin-mediated tumor-stroma interaction in melanoma progression.
Xio Y, Zhou L, Andl T, Zhang Y Res Sq. 2023; .
PMID: 37546745 PMC: 10402251. DOI: 10.21203/rs.3.rs-2944243/v3.
Sheta M, Yoshida K, Kanemoto H, Calderwood S, Eguchi T Int J Mol Sci. 2023; 24(6.
PMID: 36982267 PMC: 10049278. DOI: 10.3390/ijms24065168.
Eguchi T, Csizmadia E, Kawai H, Sheta M, Yoshida K, Prince T Cells. 2022; 11(24).
PMID: 36552758 PMC: 9777339. DOI: 10.3390/cells11243993.
Proteomics-Based Identification of Dysregulated Proteins in Breast Cancer.
Neagu A, Jayathirtha M, Whitham D, Mutsengi P, Sullivan I, Petre B Proteomes. 2022; 10(4).
PMID: 36278695 PMC: 9590004. DOI: 10.3390/proteomes10040035.